Table 1.
Clinicopathologic features of the examined cases with dural-based metastases
| Case number | Age/Sex | Location | Radiology Impression | Immunoprofile | Path Proposed Primary | Confirmed Primary | Mode of Primary Confirmation | Follow-up |
|---|---|---|---|---|---|---|---|---|
| 1 | 78/M | Frontal, temporal, and parietal | Multiple meningiomatosis | PSA+, CK7-, CK20- | Prostate | Prostate | Chart review; Previous outside diagnosis | Lost to follow-up immediately after surgery |
| 2 | 75/M | L parietal | Meningioma | Pankeratin+, PSA+, CK7-, CK20-, TTF1-, PR- | Prostate | Prostate | CT showing enlarged prostate with bladder invasion | Alive 2 months+after surgery |
| 3 | 59/F | L frontal | Meningioma | Pankeratin+, CK7+, CK20-, TTF1-, CDX2-, ER-, PR- | Breast | Breast | Subsequent breast biopsy showing invasive ductal carcinoma | Alive 9 months+after surgery |
| 4 | 80/M | R parietooccipital | Meningioma | Pankeratin+, CK7+, TTF1+, CK20-, CDX2- | Lung | Lung | CT showing lung mass with hepatic and adrenal metastases | Alive 3 years+after surgery |
| 5 | 71/F | L frontal | Meningioma or metastasis | CK20+, CK19+, CDX2+, CK7-, TTF1- | Colorectal | Colon | Outside hospital colon resection | Alive 2 years+after surgery |
| 6 | 59/M | R parietal | GBM involving dura | CK7+, CK19+, CK20-, TTF1-, CDX2- | Lung, upper Gastrointestinal, pancreaticobiliary, or head & neck | Lung | PET showing lung mass | Alive 2.5 years+after surgery |
| 7 | 64/M | R frontotemporoparietal | En-plaque meningioma | PSA+ | Prostate | Prostate | History of prostatic carcinoma | Alive a few days after surgery |
M: male; F: female; R: right; L: left; GBM: glioblastoma multiforme; PSA: Prostate specific antigen; CK: cytokeratin; TTF: thyroid transcription factor; PR: progesterone receptor; CDX: caudal-related homeobox; ER: estrogen receptor; CT: computed tomography; PET: positron emission tomography